openPR Logo
Press release

Angelman Syndrome Treatment Market Size, Treatment Drugs Report 2034

10-14-2024 02:07 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Angelman Syndrome Market

Angelman Syndrome Market

Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Angelman Syndrome Market by downloading the comprehensive report from DelveInsight @ Angelman Syndrome Treatment Market Size- https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Angelman Syndrome Market
• In September 2024:- Hoffmann-La Roche- A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion Angelman Syndrome (AS) aged 5-17 years (inclusive) will be enrolled in the study.
• The growth of the Angelman syndrome market is expected to be primarily driven by an expanding patient population and the anticipated introduction of new therapies.
• According to the Angelman Syndrome Foundation, Angelman syndrome is a rare neuro-genetic disorder that occurs in one in 15,000 live births or 500,000 people worldwide. It is caused by a loss of function of the UBE3A gene on the 15th chromosome derived from the mother.
• According to the National Organization for Rare Disorders, Angelman syndrome affects males and females in equal numbers. The prevalence is estimated to be approximately 1 in 12,000-20,000 people in the general population.
• As per Angelman UK, Angelman syndrome is a rare neurological disorder affecting around 1:20,000 births. Characteristic features include delayed development, severe learning difficulties, little or no speech, and issues with movement and balance.
• The leading Angelman Syndrome Companies such as GeneTx Biotherapeutics, GEXVal, Ionis Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Roche, Sarepta Therapeutics, StrideBio, Taysha Gene Therapies, Ultragenyx Pharmaceutical, and many others.
• Promising Angelman Syndrome Therapies such as ION582, GTX-102, and others.

Gain a competitive edge in the Angelman Syndrome Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Angelman Syndrome Treatment Drugs- https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Angelman Syndrome Epidemiology Segmentation in the 7MM
• Total Angelman Syndrome Prevalent Cases
• Total Angelman Syndrome Diagnosed Prevalent Cases
• Angelman Syndrome Cases associated with Clinical Manifestations
• Angelman Syndrome Treated Cases

Angelman Syndrome Market Insights
Medication such as RISPERDAL (risperidone) may be used to manage hyperactive and socially disruptive behavior, but this should not be used as a long-term solution. Acid reflux (or gastroesophageal reflux) can be common in Angelman syndrome. It can be treated by maintaining an upright position during and after eating, or with medication such as Gaviscon and ranitidine. Also, in rare and extreme cases, a type of surgery called fundoplication may be required. Feeding challenges can be addressed with modified breastfeeding techniques and specialized nipples for infants with suckling difficulties. Gastroesophageal reflux may be managed through upright positioning and medications that promote food passage through the digestive tract. In severe cases, surgical tightening of the esophageal sphincter may be necessary. Constipation can be treated with laxatives.

Discover key developments and opportunities in the Angelman Syndrome Market. Click here to learn more from DelveInsight's latest report @ Angelman Syndrome Market Size- https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Angelman Syndrome Treatment Market
Current treatment strategies for Angelman syndrome encompass a multidisciplinary approach aimed at managing symptoms and enhancing quality of life. While there is no cure for Angelman syndrome, interventions such as seizure management with antiepileptic drugs and behavioral therapies play a crucial role in symptom control. Communication support through augmentative and alternative communication methods, along with physical and occupational therapy, targets developmental delays and improves functional abilities. Additionally, supportive services such as special education and support groups provide essential resources for individuals with Angelman syndrome and their families. Ongoing research into experimental therapies, including gene therapy and targeted pharmacological interventions, offers hope for future advancements in Angelman syndrome treatment.

Angelman Syndrome Emerging Drugs Profile
• ION582: Ionis Pharmaceuticals
• GTX-102: Ultragenyx Pharmaceutical
• NNZ-2591: Neuren Pharmaceuticals

Download DelveInsight's Angelman Syndrome Market report today and stay ahead in this rapidly evolving field. @ Angelman Syndrome Clinical Trials- https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Angelman Syndrome Market Report
• Coverage- 7MM
• Angelman Syndrome Companies- GeneTx Biotherapeutics, GEXVal, Ionis Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Roche, Sarepta Therapeutics, StrideBio, Taysha Gene Therapies, Ultragenyx Pharmaceutical, and many others.
• Angelman Syndrome Therapies- ION582, GTX-102, and others
• Angelman Syndrome Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Angelman Syndrome Unmet Needs, KOL's views, Analyst's views, Angelman Syndrome Market Access and Reimbursement

Download the report to understand which factors are driving Angelman Syndrome Market Trends @ Angelman Syndrome Market Trends- https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Angelman Syndrome
3. Competitive Intelligence Analysis for Angelman Syndrome
4. Angelman Syndrome: Market Overview at a Glance
5. Angelman Syndrome: Disease Background and Overview
6. Patient Journey
7. Angelman Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Angelman Syndrome Unmet Needs
10. Key Endpoints of Angelman Syndrome Treatment
11. Angelman Syndrome Marketed Products
12. Angelman Syndrome Emerging Therapies
13. Angelman Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Angelman Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight


List of Top Selling Market Research Reports in 2024

stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
pigment epithelial detachment market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Neuroendocrine Tumor Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market
medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
mouth neoplasms market- https://www.delveinsight.com/report-store/mouth-neoplasms-market
urinary retention market- https://www.delveinsight.com/report-store/urinary-retention-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
skin neoplasm market- https://www.delveinsight.com/report-store/skin-neoplasms-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
wilms tumor market- https://www.delveinsight.com/report-store/wilms-tumor-market
rhabdomyosarcoma market- https://www.delveinsight.com/report-store/rhabdomyosarcoma-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angelman Syndrome Treatment Market Size, Treatment Drugs Report 2034 here

News-ID: 3691357 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Angelman

Angelman Syndrome Market to Set Phenomenal Growth From 2025 to 2034
Introduction Angelman Syndrome (AS) is a rare neurogenetic disorder caused by the loss of function of the UBE3A gene on chromosome 15. It is characterized by severe developmental delays, intellectual disability, speech impairment, seizures, and distinctive behavioral traits such as frequent smiling and excitability. Affecting approximately 1 in 12,000-20,000 live births, Angelman Syndrome has historically lacked targeted treatment options, with management focused primarily on symptom relief. However, growing research in gene therapies,
Angelman Syndrome Market Is Booming Worldwide 2025-2032 | Roche Biogen,Ionis Pha …
According to the latest research from Coherent Market Insights, the Angelman Syndrome Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough research, highlighting current trends, financial performance, and historical data evaluation. The company profiles within the report are derived from the current performance of the Angelman Syndrome Market, considering key factors such as drivers, trends, and challenges, as
Angelman Syndrome Treatment Market Size is expected to grow by 2034, estimates D …
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence. DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and
Angelman Syndrome Treatment Market Size is expected to grow by 2034, estimates D …
Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence. DelveInsight's "Angelman Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Angelman Syndrome, historical and
Angelman Syndrome Market Report 2023-2033 | Industry Size, Analysis and Latest I …
Market Overview: The 7 major Angelman syndrome markets are expected to exhibit a CAGR of 4.4% during 2023-2033. The report offers a comprehensive analysis of the angelman syndrome market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven
Angelman Syndrome Treatment Market would rocket up to USD 220.64 million by 2030
The incidence of angelman syndromes can vary among different populations and age groups. However, the increase in government initiatives in developing treatment options for angelman syndrome drives the global angelman syndrome treatment market. Moreover, increased health and R&D expenditure also boosts the market growth. Data Bridge Market Research analyses that the angelman syndrome treatment market which was USD 143.77 million in 2022, would rocket up to USD 220.64 million